Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06609343 · ClinicalTrials.gov registry record · Phase 1
Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis
A Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Not yet
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT06609343 is a Phase 1 study that has not yet begun recruiting, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 16 participants.
The verdict
NCT06609343, a Phase 1 study, has not yet begun recruiting, sponsored by The University of Texas Health Science Center at San Antonio.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
Fatigue is the most common symptom reported by end-stage kidney disease patients on maintenance hemodialysis. Unfortunately, there currently is no medical management for this overwhelming feeling of tiredness. As a result, patients continue to suffer with poor quality of life and impaired daily activities. The purpose of this pilot trial is to find out if bupropion (a medicine commonly prescribed for stopping smoking, seasonal mood disorder, and depression) may help lessen fatigue in hemodialysis patients. In this study, hemodialysis participants will receive bupropion tablet orally three times a week during routine dialysis procedure for consecutive 8 weeks. Study participants will complete a battery of questionnaires to self-report fatigue, cognition, and quality of life. The study team will collect biological specimens. All these procedures will be performed at the dialysis clinic during routine dialysis procedure.
Interventions
- DRUG Bupropion Hydrochloride 150 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06609343
The ClinicalTrials.gov registry entry for NCT06609343 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bupropion Hydrochloride 150 MG is the first listed.
NCT06609343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06609343 about?
NCT06609343 is a clinical study titled "Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis". Fatigue is the most common symptom reported by end-stage kidney disease patients on maintenance hemodialysis. Unfortunately, there currently is no medical management for this overwhelming feeling of tiredness. As a result, patients continue to suffer with poor quality of life and impaired daily acti...
What is the current status of trial NCT06609343?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2026-06-01. Estimated completion is 2027-01-30.
What interventions are being tested in trial NCT06609343?
The interventions under investigation include: Bupropion Hydrochloride 150 MG (DRUG).
Who is sponsoring clinical trial NCT06609343?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.